"Bivalent mRNA COVID-19 Vaccines Reduce Thromboembolic Events in Elderly and End Stage Renal Disease Patients: US Study"

A study conducted among Medicare beneficiaries aged ≥65 years and those with end stage renal disease (ESRD) receiving dialysis found that bivalent mRNA COVID-19 vaccines were 47% effective in preventing thromboembolic events among immunocompetent persons aged ≥65 years and 51% effective among adults aged ≥18 years with ESRD, compared with receipt of the original monovalent vaccines alone. The findings suggest that COVID-19 vaccines provide protection against COVID-19–related thromboembolic events, emphasizing the importance of staying up to date with COVID-19 vaccination to prevent complications.